Progesterone impairs Herceptin effect on breast cancer cells

  • Authors:
    • Kamila Kitowska
    • Agnieszka Kowalska
    • Magdalena Mieszkowska
    • Dominika Piasecka
    • Andrzej C. Skladanowski
    • Hanna M. Romanska
    • Rafal Sadej
  • View Affiliations

  • Published online on: November 27, 2017     https://doi.org/10.3892/ol.2017.7493
  • Pages:1817-1822
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

Breast cancer (BCa) is the most common cancer affecting women worldwide. Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in ~20‑25% of invasive ductal breast carcinomas and is associated with the more aggressive phenotype. Herceptin, a humanized antibody against HER2, is a standard therapy in HER2‑overexpressing cases. Approximately one‑third of patients relapse despite treatment. Therefore numerous studies have investigated the molecular mechanisms associated with Herceptin resistance. An interaction between HER2 signalling and steroid hormone receptor signalling pathways has been previously investigated, but the effect of this relationship on Herceptin resistance has never been studied. The present study analysed an impact of the steroid hormone, progesterone (PG), on Herceptin‑dependent cell growth inhibition. Results indicated that Herceptin‑inhibited proliferation of breast cancer cell lines overexpressing HER2 (BT474 and MCF/HER2) in 3D culture is abolished by PG. Furthermore, results demonstrated that PG led to the activation of HER2/HER3‑mediated signalling. Moreover, PG treatment induced a shift of Herceptin‑dependent cell cycle arrest in G1 phase towards S and G2 phases with concomitant upregulation of cyclin‑dependent kinase 2 (CDK2) and downregulation of CDK inhibitor p27Kip1. These results demonstrate for the first time PG involvement in the failure of Herceptin treatment in vitro. The present observations suggest that cross‑talk between PG‑ and HRG/HER2‑initiated signalling pathways may lead to the acquisition of resistance to Herceptin in patients with BCa.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kitowska, K., Kowalska, A., Mieszkowska, M., Piasecka, D., Skladanowski, A.C., Romanska, H.M., & Sadej, R. (2018). Progesterone impairs Herceptin effect on breast cancer cells. Oncology Letters, 15, 1817-1822. https://doi.org/10.3892/ol.2017.7493
MLA
Kitowska, K., Kowalska, A., Mieszkowska, M., Piasecka, D., Skladanowski, A. C., Romanska, H. M., Sadej, R."Progesterone impairs Herceptin effect on breast cancer cells". Oncology Letters 15.2 (2018): 1817-1822.
Chicago
Kitowska, K., Kowalska, A., Mieszkowska, M., Piasecka, D., Skladanowski, A. C., Romanska, H. M., Sadej, R."Progesterone impairs Herceptin effect on breast cancer cells". Oncology Letters 15, no. 2 (2018): 1817-1822. https://doi.org/10.3892/ol.2017.7493